Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2655 - An Estimation of the Population Survival Benefit of First-course Chemotherapy for Head and Neck Cancers.

Date

10 Sep 2017

Session

Poster display session

Presenters

Viet Do

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

V. Do, W. Ng, S. Jacob, G.P. Delaney, M. Barton

Author affiliations

  • Collaboration For Cancer Outcomes Research And Evaluation (ccore), Ingham Institute for Applied Medical Research, University of New South Wales, Sydney, 2750 - Liverpool/AU
More

Resources

Abstract 2655

Background

Randomised clinical trials describe the benefit of chemotherapy for specific head and neck patients with selected patient and tumour characteristics. This study estimates the overall survival benefit of chemotherapy above all other modalities for the whole population of head and neck cancer patients in Australia, if evidence-guidelines were followed.

Methods

Decision trees with evidence-based indications for chemotherapy have been previously defined. For all defined indications, the highest level of clinical evidence available was identified. Multiple electronic citation databases were systematically queried, including Medline and Cochrane library. The benefits of first-course chemotherapy were estimated for 1-year and 5-year overall survivals. To assess the robustness of our estimates, univariate and multivariate analyses were performed.

Results

The estimated 1-year and 5-year absolute population-based survival benefits of optimally utilised chemotherapy for head and neck cancer patients in Australia are 5.5% (95% Confidence Interval, CI, 4.5%-6.8%) and 4.2% (95% CI, 3.6%-5.0%), respectively.

Conclusions

First-course chemotherapy improved population-based survival in head and neck cancer patients, when used in accordence with guidelines recommendations. Measurement of population survival benefits of cancer treatment is important as these can provide salient inputs for economic analyses, aid in priority setting in cancer program and guide quality improvement according to evidence-based guidelines.

Clinical trial identification

Legal entity responsible for the study

CCORE, Ingham Institute for Applied Medical Research, Sydney, Australia.

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.